Predict your next investment

Aeovian Pharmaceuticals company logo
HEALTHCARE | Biotechnology
aeovian.com

See what CB Insights has to offer

Founded Year

2012

Stage

Series A | Alive

Total Raised

$38.26M

Last Raised

$37M | 2 yrs ago

About Aeovian Pharmaceuticals

Aeovian is a San Francisco based biopharmaceutical company developing highly selective therapeutics modulating mTORC1 pathway. The company was founded with technology licensed from The Buck Institute for Research on Aging. Aeovian's candidates are poised to overcome the clinical limitations of current mTOR inhibitors, namely their deleterious side effects on metabolic health and immune function that arise from their off-target inhibition of mTORC2.

Aeovian Pharmaceuticals Headquarter Location

712 Bancroft Road #241

Walnut Creek, California, 94598,

United States

Latest Aeovian Pharmaceuticals News

Aeovian Pharmaceuticals Raises $37 Million Series A Financing to Advance Selective mTORC1 Inhibitors

Jan 8, 2020

venBio Partners and Sofinnova Investments co-lead Series A round alongside Apollo Health Ventures with Evotec SE joining the current round October 03, 2019 08:00 AM Eastern Daylight Time SAN FRANCISCO--( BUSINESS WIRE )-- Aeovian Pharmaceuticals , a company developing innovative therapies for the treatment of rare and age-related diseases, today announced the close of a $37 million Series A financing co-led by venBio Partners and Sofinnova Investments, alongside founding investors Apollo Health Ventures and Evotec SE. The proceeds from this financing will be used to advance its lead selective mTORC1 inhibitor, AE116, from the preclinical stage through clinical proof of concept for an undisclosed rare disease of the central nervous system (CNS). “The strong financial support and expertise from our investors will enable Aeovian to realize the full potential of our mTORC1 modulation approach,” said Stelios T. Tzannis, MS/PhD, President & CEO of Aeovian. “I am particularly excited to have the added expertise and wealth of knowledge that the venBio and Sofinnova teams bring to Aeovian to advance the development of our promising mTORC1-selective inhibitor for our first rare disease indication.” Richard Gaster, MD, PhD, Principal at venBio, and Mike Powell, PhD, Managing General Partner at Sofinnova Investments, will join Jens Eckstein, PhD, Managing Partner at Apollo Health Ventures on Aeovian’s Board of Directors. Yvonne Yamanaka, PhD, Vice President at venBio, and Sarah Bhagat, PhD, Principal at Sofinnova, will join as Board Observers. Aeovian’s proprietary platform is supported by an extensive intellectual property portfolio, part of which has been obtained by assignment from the Buck Institute of Novato, California, the nation's first independent research facility focused solely on understanding the connection between aging and chronic disease. “We believe that Aeovian’s differentiated and selective mTORC1 inhibitor approach can have broad application in rare diseases with high unmet need,” said Richard Gaster, a venBio Principal and Aeovian Director. “We look forward to initially pursuing rare CNS disease indications, but can see a large opportunity to also target age-related diseases more broadly.” “We are truly delighted to welcome these experienced life science venture firms to Aeovian,” said Jens Eckstein, Managing Partner at Apollo Health Ventures, “It strengthens our mission at Apollo to discover and develop novel medicines for age-related diseases.” About Aeovian Pharmaceuticals Inc. Aeovian Pharmaceuticals, Inc. focuses on the discovery and development of novel, highly selective mTORC1 inhibitors for the treatment of rare and age-related diseases. The Company was founded with technology licensed from The Buck Institute for Research on Aging. Aeovian’s lead candidates are poised to overcome the clinical limitations of current mTOR inhibitors, namely their deleterious side effects on metabolic health and immune function that arise from their off-target inhibition of mTORC2. Aeovian’s lead compounds are novel, highly selective modulators of the mTORC1 pathway with the potential to address multiple underlying causes of disease initiation and progression, such as oxidative, cellular, and environmental stress. About venBio Partners venBio Partners is a life sciences investment firm that partners with industry leaders to build innovative medicines and technologies, with a focus on novel therapeutics for unmet medical needs. For more information, please visit www.venbio.com . About Sofinnova Investments Sofinnova Investments is a biopharmaceutical investment firm with approximately $2.1B in assets under management. We invest in both private and public therapeutics-focused biotech companies, in both the U.S. and Europe, across all stages of company formation and growth. We seek to build world class companies that aspire to dramatically improve the current state of medical care today and ultimately, the lives of patients. For more information, please visit www.sofinnova.com . About Apollo Health Ventures Apollo Health Ventures is an early-stage investment firm based in Europe and the U.S. focusing on translating breakthrough discoveries in geroscience. Apollo Health Ventures focuses on assets, platforms and modalities with the potential to treat, prevent, or even reverse age-related diseases such as neurodegenerative disease, cardiovascular disease, sarcopenia, frailty, and cancer, with the ultimate goal of increasing healthy human lifespan. Apollo actively works with scientists and entrepreneurs to create new ventures, and engages in hypothesis-driven company building. For more information, please visit www.apollo.vc . About Evotec SE Evotec is a drug discovery alliance and development partnership company focused on rapidly progressing innovative product approaches through highest quality stand-alone and integrated drug discovery and development solutions. For more information, please visit www.evotec.com . Contacts

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Aeovian Pharmaceuticals

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Aeovian Pharmaceuticals is included in 1 Expert Collection, including Biopharmaceuticals.

B

Biopharmaceuticals

5,732 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

Aeovian Pharmaceuticals Patents

Aeovian Pharmaceuticals has filed 2 patents.

The 3 most popular patent topics include:

  • Human proteins
  • Rare diseases
  • Signal transduction
patents chart

Application Date

Grant Date

Title

Related Topics

Status

9/17/2020

6/1/2021

Human proteins, V8SuperTourer drivers, Signal transduction, Amines, Rare diseases

Grant

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

Application Date

9/17/2020

00/00/0000

Grant Date

6/1/2021

00/00/0000

Title

Subscribe to see more

Related Topics

Human proteins, V8SuperTourer drivers, Signal transduction, Amines, Rare diseases

Subscribe to see more

Status

Grant

Subscribe to see more

Aeovian Pharmaceuticals Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Aeovian Pharmaceuticals Rank

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.